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ABSTRACT
Background: Exhaled nitric oxide (eNO) is a useful marker of eosinophilic airway inflammation in asthmatics.
There have been no studies to show the relationship between eNO measured by offline methods and the de-
gree of bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids.
Methods: The study population comprised asthmatics at our outpatient clinic. We measured eNO levels by
two methods (“eNOs” was measured with a Sievers kit; and “eNOc” was measured with a kit from the Center
for Environmental Information Science, Japan). We also used spirometry to test bronchial hyperresponsive-
ness to acetylcholine (PC20Ach).
Results: We recruited 192 stable asthmatics. There was a significant relationship between eNOs and eNOc
(r = 0.919, p < 0.001). LogPC20Ach levels were negatively correlated with eNOs or eNOc levels (eNOs, r =
−0.31, p < 0.001; eNOc, r = −0.23, p = 0.0013). We classified the subjects into two groups based on eNOs lev-
els ( (A) the subjects with high eNOs levels (n = 92) and (B) the subjects with normal eNOs levels (n = 100) ) ;
logPC20Ach was significantly correlated with eNOs (r = −0.34, p = 0.001) or eNOc (r = −0.28, p = 0.0075) but not
correlated with %FEV1 in (A), whereas logPC20Ach was not significantly correlated with eNO but significantly
correlated with %FEV1 (r = 0.33, p = 0.002) in (B).
Conclusions: Levels of eNOs and eNOc were correlated with the degree of bronchial hyperresponsiveness
to acetylcholine in adult asthmatics treated with inhaled corticosteroids. Our findings suggest that offline moni-
toring of eNO will facilitate the management of bronchial asthma in patients treated with these drugs.
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ABBREVIATIONS
eNO, exhaled nitric oxide; BHR, bronchial hyperresponsiveness; CEIS, The Center for Environmental Informa-
tion Science (Tokyo, Japan); PC20Ach, provocative concentration of acetylcholine in inhaled aerosols that leads
to a 20% fall in FEV1.
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INTRODUCTION
Bronchial asthma is characterized by eosinophilic
bronchial inflammation. Inhaled corticosteroids
(ICS), the mainstay of asthma treatment, are effective
because they prevent this inflammatory process.
Therefore, the quantification of airway inflammation
may provide additional information for both the diag-
nosis and management of bronchial asthma. How-
ever, the current asthma management guideline
(GINA: Global Initiative for Asthma) relies on the
monitoring of respiratory function and symptoms.1
Three studies have demonstrated that the addition of
alternative monitoring markers, such as bronchial hy-
perresponsiveness (BHR), eosinophilia in induced
sputum, and exhaled nitric oxide (eNO) concentra-
tion, to the current guidelines on dose adjustment of
ICS leads to improved outcomes.2-4
According to the recent studies, eNO is a useful
marker of airway eosinophilic inflammation in
asthma.5,6 The increased levels of eNO are due to the
activation of NO synthase in airway epithelial and in-
flammatory cells.7-9 Measurement of eNO is simple,
noninvasive, and repeatable. eNO levels are higher in
asthmatics than in healthy subjects,10 and eNO levels
fall after treatment with corticosteroids.11 In asthmat-
ics treated with ICS, eNO levels are correlated with
the following markers of disease control: asthma
symptoms within the past 2 weeks, disease score, and
reversibility of airflow obstruction.12 eNO is useful in
the clinical management of asthmatic patients treated
with ICS.4
However, despite the utility of eNO measurement,
NO analyzers are too expensive for widespread use
by general practitioners, for whom the offline (bag
collection) method of eNO measurement may be
more affordable.5,6,13 In our previous study, eNO
measurements taken with a Sievers (Sievers Instru-
ments Division, Ionics, Inc., Boulder, CO) bag collec-
tion kit were significantly correlated with the level of
bronchial reversibility and airway eosinophilic inflam-
mation both in patients on ICS and not on ICS.14 Also,
recent studies have shown that the results obtained
with a new offline method developed by the Center
for Environmental Information Science (CEIS) in To-
kyo is equivalent to those with the online method.15,16
We sought to investigate the relationship between
the eNO levels measured by these two offline meth-
ods and the level of BHR in Japanese asthmatic pa-
tients.
METHODS
SUBJECTS
The study population was recruited from adult outpa-
tients with bronchial asthma (n = 192) at the Clinic of
Allergy and Respiratory Medicine, Sagamihara Na-
tional Hospital, between June 2003 and April 2005. All
patients gave full informed consent to participate in
the study. Each subject underwent a standard clinical
assessment, which included history, physical exami-
nation, and chest radiography. The diagnosis of
asthma was based on application of the GINA guide-
line performed by an experienced respiratory physi-
cian blinded to the results of eNO measurement.1
Therapy was chosen in accordance with this guide-
line.1 Atopy was indicated by a positive skin test to
mites or house dust or by serum IgE >250 IUmL.
Exclusion criteria included current smokers or ex-
smokers of >20 pack-years, rescue use of oral corti-
costeroids within the preceding 4 weeks, pregnancy,
and any other respiratory disease. The study protocol
was approved by the Ethics Committee at our hospi-
tal (no. 14, 2003).
MEASUREMENT OF eNOs AND eNOc
Exhaled air was collected with Sievers bag collection
kits in accordance with the method used previ-
ously14,17 and by the CEIS method reported by Mu-
nakata et al.15 Briefly, subjects took a deep breath of
room air through the NO scavenging filter and ex-
haled through a mouthpiece with a flow rate of 70
mLs against an expiratory resistance of 10 cm H2O;
5 seconds later, the exhaled air was collected into the
1.5-L Mylar bag provided in the kit. Immediately after
the collection by Sievers’s kit, Exhaled air was col-
lected with the CEIS kit. Subjects took a deep breath
of room air and exhaled through a mouthpiece with a
flow rate of 50 mLs against an expiratory resistance
of 15 cm H2O; 5 seconds later, exhaled air was col-
lected into the 1.5-L Mylar bag provided in the kit.
The NO concentration in the collected exhaled air
was stored at room temperature and measured within
12 hours. The air was drawn out of the balloons at
200 mLmin into an NO chemiluminescence analyzer
(NOA model 280A, Sievers Instruments) with a re-
sponse time of 200 milliseconds. Measurements of
eNO were labeled “eNOs” (taken with the Sievers
kit) and “eNOc” (taken with the CEIS kit). On the ba-
sis of recent studies, the levels of eNOs are about 80%
of those with online methods14,17 and the levels of
eNOc are equivalent to those with online methods.15
MEASUREMENT OF BHR TO ACETYLCHOLINE
Inhalation testing was performed by a modification of
the method described by Chai et al.18 Acetylcholine
chloride (Ach; Ovisort; Daiichi Pharmaceutical Co.,
Ltd., Tokyo, Japan) at concentrations of 0.156, 0.313,
0.625, 1.25, 2.5, 5, 10, and 20 mgmL was prepared by
dilution in buffered saline solution (pH 7.4). After the
exhaled air samples for eNO measurement had been
collected, all subjects underwent spirometry with an
electric spirometer (Minato Autospiro AS-303; Minato
Medical Science Co., Ltd., Osaka, Japan). Subjects in-
haled Ach aerosol from a nebulizer (DeVilbiss 646;
DeVilbiss Co., Somerset, PA) by tidal breathing for 2
minutes. The operating airflow rate of this device was
eNO and Bronchial Hyperresponsiveness
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Fig. 1 Corelation between eNOs and eNOc (r＝ 0.919, 
p＜ 0.001).
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Table 1 Patient demographics
192No.
  59/133Sex (M/F)
48.9±16.6Age
125/67Atopy/non-atopy
7.69±8.66Duration of ICS therapy (year)
963±705The dose of ICS 
(mcg/day, beclomethasone equivalent)
2.32±0.71FEV1 (L)
88.6±15.6%FEV1 (% of predicted)
66.0±22.8%MMF (% of predicted)
67.6±25.0%V50 (% of predicted)
3.80±0.72LogPC20Ach
4.0 (2.9―5.1) Eosinophils in peripheral blood (%)
25.5 (20.8―30.2)eNOSIEVERS (ppb)
34.3 (28.0―40.6)eNOCEIS (ppb)
The data are presented as mean ± SD, or as median (the 
range of 95%CI).
5 Lmin. Subjects inhaled the Ach aerosol at increas-
ing concentrations until the FEV1 fell by >20% of its
baseline value or until maximum concentration. Bron-
chial sensitivity was expressed as PC20Ach and was de-
fined as the provocative concentration of the agonist
in the inhaled aerosol leading to a fall in FEV1 of 20%.
PC20Ach was estimated by linear interpolation.
STATISTICAL ANALYSIS
Data are shown as means ± SD, but shown as median
and their 95% confidence interval (CI) for eosinophils
in peripheral blood, eNOs and eNOc. Correlations
were determined by the Spearman rank correlation.
A paired sample t test was used to analyze parame-
ters between the group with high eNOs and that with
normal eNOs in Table 2. p < 0.05 was considered sig-
nificant.
RESULTS
We recruited 192 stable asthmatics for the study (Ta-
ble 1). All subjects were treated with ICS and were
asymptomatic. There was a significant correlation be-
tween eNOs and eNOc (r = 0.919, p < 0.001, Fig. 1).
There was a weakly significant correlation between
%FEV1 and eNOs or eNOc (eNOs, r = −0.19, p =
0.011, Fig. 2A; eNOc, r = −0.19, p = 0.012, Fig. 2B).
LogPC20Ach was significantly negatively correlated
with eNOs or eNOc (eNOs, r = −0.31, p < 0.001, Fig.
3A; eNOc, r = −0.23, p = 0.0013, Fig. 3B). In the 71
subjects who consented to the collection of peripheral
blood samples, the percentage of eosinophils in the
blood was significantly correlated with eNOs or
eNOc (eNOs, r = 0.40, p = 0.0018, Fig. 4A; eNOc, r =
0.37, p = 0.0017, Fig. 4B).
In the previous study,21 there was no relationship
between BHR and eNO in well-controlled asthmatics
treated with ICS. For the purpose of comparing the
previous study and our study, we classified the sub-
jects into two groups based on the level of eNOs; (A)
the group with high eNOs levels (eNOs≧ 27.2 ppb)
and (B) that with normal eNOs levels (eNOs < 27.2
ppb). The normal range of eNOs was determined in
14 healthy, non-atopic, non-smoking volunteers (me-
dian 21.1 ppb, 95%CI was 15.0―27.1 ppb). As shown in
Table 2, %FEV1, %MMF, %V50, logPC20 was signifi-
cantly decreased and eosinophils in the peripheral
blood were significantly increased in (A), compared
with (B). Moreover, as shown in Table 3, there was a
significant relationship between logPC20Ach and
eNOs, eNOc, or eosinophils in blood, but no signifi-
cant relationship between logPC20Ach and %FEV1,
%MMF or %V50 in (A). On the contrary, in (B) group,
there was a significant relationship between
logPC20Ach and %FEV1, %MMF or %V50, but no signifi-
cant relationship between logPC20Ach and eNOs,
eNOc, or eosinophils in blood.
DISCUSSION
In asthmatics treated with ICS, eNOs and eNOc were
significantly negatively associated with logPC20Ach.
There has been controversy over the relationship
between eNO and BHR levels in steroid-treated asth-
matics. In over 8000 steroid-naïve adolescents in Nor-
way, eNO levels were significantly related to BHR lev-
els.19 Several studies have shown that, in steroid-
naïve asthmatics, eNO levels were correlated with the
degree of BHR in response to methacholine or hista-
mine, but there was no such correlation in steroid-
treated asthmatics.20-22 However, in contrast, Reid
and coworkers showed that, in steroid-treated asth-
Tsuburai T et al.
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Fig. 2 Corelation between eNO and %FEV1. (A) eNOs (r＝－0.19, p＝0.011) and (B) eNOc (r＝－0.19, p＝0.012).
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Fig. 3 Corelation between eNO and logPC20Ach. (A) eNOs (r＝ －0.31, p＜0.001) and (B) eNOc (r＝ －0.23, p＝
0.0013).
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matics, eNO levels were correlated with the degree of
BHR to methacholine.23
There are two possible explanations for these con-
tradictory results: one is the difference between eNO
and BHR in terms of their response to ICS therapy,
and the other is the difference in the types of subjects
recruited in each of these previous studies. The eNO
level reflects airway eosinophilic inflammation. eNO
level and the percentage of eosinophils in the periph-
eral blood were significantly correlated, and their re-
lationship was comparable to that in a recent
study.14,23 These findings suggest that eNO is a use-
ful marker of eosinophilic airway inflammation in pa-
tients treated with ICS. Airway inflammation causes
BHR, but the levels of BHR not only reflected the air-
way inflammation but also remodeling or lung func-
tion. Moreover, eNO behaves as a rapid response
marker. In previous studies, ICS therapy decreased
eNO and Bronchial Hyperresponsiveness
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Fig. 4 Corelation between eNO and eosinophil count (%) in peripheral blood in 71 asthmatics. (A) eNOs (r＝ 0.40, 
p＝ 0.0018) and (B) eNOc (r＝0.37, p＝0.0017).
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Table 2 Patients demographics based on the levels of eNOs
p-value(B) eNOs＜27.2 ppb(A) eNOSIEVERS≧27.2 ppb
10092No.
0.138.58±9.636.72±7.39Duration of ICS therapy (year)
0.451000±777 923±617The dose of ICS(mcg/day, beclomethasone equivalent)
0.00791.7±14.885.3±15.7%FEV1 (% of predicted)
0.0968.6±23.563.1±21.8%MMF (% of predicted)
0.2669.5±25.165.4±24.8%V50 (% of predicted)
0.0013.93±0.483.66±0.59LogPC20Ach
0.0095.0 (3.1―6.9) 5.9 (4.4―7.4) Eosinophils in peripheral blood (%)
16.0 (14.6―17.4)40.1 (32.2―48.0)eNOSIEVERS (ppb)
20.2 (17.8―22.7)60.2 (49.9―70.5)eNOCEIS (ppb)
The data are presented as mean ± SD, or as median (the range of 95%CI).
27.1 ppb was the limited value of normal range in eNOSIEVERS.
The range was determined in 14 healthy, non-atopic, non-smoking volunteers (median 21.1 ppb, 95%CI was 15.0―27.1 ppb).
Table 3 Relationship between logPC20Ach and other parameters
(B) eNOs＜27.2 ppb(A) eNOSIEVERS≧27.2 ppb
p-valuerp-valuer
　0.0020.330.790.028%FEV1 (% of predicted)
＜0.0010.480.080.18%MMF (% of predicted)
＜0.0010.490.110.16%V50 (% of predicted)
　0.4680.130.021－0.37Eosinophils in peripheral blood (%)
　0.211－0.120.001－0.34eNOSIEVERS (ppb)
　0.662－0.040.0075－0.28eNOCEIS (ppb)
r: Pearson corelation coeficient between PC20Ach and other parameters.
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the eNO level within 4 weeks, whereas BHR took 8
weeks or more to respond to ICS.24 These findings
suggest that eNO and BHR were significantly corre-
lated, but we should pay attention to the difference of
these two factors.
In previous studies in which eNO levels were not
correlated with BHR in ICS-treated subjects,20,21 the
subjects were well-controlled with ICS (asymptomatic
and with almost normal function and normal eNO lev-
els; a substantial proportion had negative inhalational
challenge results). Our subjects were asymptomatic,
but about 50% of them had high eNOs levels, suggest-
ing that our subjects included patients with only
partly controlled disease (Table 2). In the subjects
with normal eNOs levels in our study, there was no
significant relationship between logPC20Ach and eNOs
or eNOc, compatible with Leuppi’s study (Table 3).
And also, in these subjects, there was a significant re-
lationship between logPC20Ach and parameters of the
pulmonary function test. This finding suggests that
BHR may reflect remodeling in asthmatics whose air
inflammation was well-controlled. On the other hand,
in the subjects with high levels of eNOs, logPC20Ach
was correlated with eNOs or eNOc, but was not cor-
related with %FEV1, %MMF, or %V50. This shows that
BHR can reflect subclinical airway inflammation.
These findings suggest that eNO is useful as a
marker of disease control in asthmatics treated with
ICS, and this is probably because eNO measurement
may detect subclinical airway inflammation. More-
over, add-on of anti-inflammatory drugs may be effec-
tive in the subjects with high eNO levels, whereas
add-on of bronchodilators may be effective in the sub-
jects with normal eNO levels and obstructive impair-
ment. The measurement of eNO can complement the
pulmonary function test as a following marker of
asthma. According to previous studies, eNO levels
were correlated with markers such as FEV1 or bron-
chial hyperresponsiveness to saline of disease con-
trol12,25 and eNO was considered useful in the clinical
management4 of ICS-treated asthmatic patients.
Reid’s study and Smith’s study support our conclu-
sion. However, further prospective studies are
needed to explain this hypothesis.
Previous studies on the relationship between BHR
and eNO were based on the online methods. In this
study, the subjects were not measured with the on-
line method, but the levels of eNOc were almost
equivalent to those with online method.14 The CEIS’s
method can be more useful due to this point, but be-
cause there are only few reports previously, we need
further studies based on CEIS’s method.
In summary, the eNO levels measured by the two
offline methods were significantly correlated with the
degree of BHR to acetylcholine in adult asthmatics
treated with ICS. Our findings suggest that monitor-
ing of NO will facilitate management of bronchial
asthma in ICS-treated patients, but we need further,
long-term studies to determine the clinical value of
following eNO levels in these patients.
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